Health & pharma news, latest stories & analysis

Find today's trending Health & pharma news & headlines

AbbVie bolsters portfolio with $10.1 billion ImmunoGen buyout for cancer therapy
  • AbbVie has acquired ImmunoGen for $10.1 billion in cash, it announced recently.
  • Integrating ImmunoGen's Elahere may be a pivotal step for AbbVie to offset Humira's declining exclusivity.
  • The acquisition is set to finalise by mid-2024.
December 1, 2023

Trading ideas & analysis

Cassava Sciences: SAVA stock plot thickens, short interest jumps
October 13, 2023
TG Therapeutics (TGTX) stock price has plunged: buy the dip?
October 11, 2023
Cassava Sciences (SAVA) stock price forms a bullish pattern: is it a buy?
October 5, 2023

More breaking stories